Cargando…
Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized
BACKGROUND: The relationship between cholesterol and prostate cancer has been extensively studied for decades, where high levels of cellular cholesterol are generally associated with cancer progression and less favorable outcomes. However, the role of in vivo cellular cholesterol synthesis in this p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922022/ https://www.ncbi.nlm.nih.gov/pubmed/29703166 http://dx.doi.org/10.1186/s12885-018-4373-y |
_version_ | 1783318129994104832 |
---|---|
author | Rye, Morten Beck Bertilsson, Helena Andersen, Maria K. Rise, Kjersti Bathen, Tone F. Drabløs, Finn Tessem, May-Britt |
author_facet | Rye, Morten Beck Bertilsson, Helena Andersen, Maria K. Rise, Kjersti Bathen, Tone F. Drabløs, Finn Tessem, May-Britt |
author_sort | Rye, Morten Beck |
collection | PubMed |
description | BACKGROUND: The relationship between cholesterol and prostate cancer has been extensively studied for decades, where high levels of cellular cholesterol are generally associated with cancer progression and less favorable outcomes. However, the role of in vivo cellular cholesterol synthesis in this process is unclear, and data on the transcriptional activity of cholesterol synthesis pathway genes in tissue from prostate cancer patients are inconsistent. METHODS: A common problem with cancer tissue data from patient cohorts is the presence of heterogeneous tissue which confounds molecular analysis of the samples. In this study we present a general method to minimize systematic confounding from stroma tissue in any prostate cancer cohort comparing prostate cancer and normal samples. In particular we use samples assessed by histopathology to identify genes enriched and depleted in prostate stroma. These genes are then used to assess stroma content in tissue samples from other prostate cancer cohorts where no histopathology is available. Differential expression analysis is performed by comparing cancer and normal samples where the average stroma content has been balanced between the sample groups. In total we analyzed seven patient cohorts with prostate cancer consisting of 1713 prostate cancer and 230 normal tissue samples. RESULTS: When stroma confounding was minimized, differential gene expression analysis over all cohorts showed robust and consistent downregulation of nearly all genes in the cholesterol synthesis pathway. Additional Gene Ontology analysis also identified cholesterol synthesis as the most significantly altered metabolic pathway in prostate cancer at the transcriptional level. CONCLUSION: The surprising observation that cholesterol synthesis genes are downregulated in prostate cancer is important for our understanding of how prostate cancer cells regulate cholesterol levels in vivo. Moreover, we show that tissue heterogeneity explains the lack of consistency in previous expression analysis of cholesterol synthesis genes in prostate cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4373-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5922022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59220222018-05-07 Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized Rye, Morten Beck Bertilsson, Helena Andersen, Maria K. Rise, Kjersti Bathen, Tone F. Drabløs, Finn Tessem, May-Britt BMC Cancer Research Article BACKGROUND: The relationship between cholesterol and prostate cancer has been extensively studied for decades, where high levels of cellular cholesterol are generally associated with cancer progression and less favorable outcomes. However, the role of in vivo cellular cholesterol synthesis in this process is unclear, and data on the transcriptional activity of cholesterol synthesis pathway genes in tissue from prostate cancer patients are inconsistent. METHODS: A common problem with cancer tissue data from patient cohorts is the presence of heterogeneous tissue which confounds molecular analysis of the samples. In this study we present a general method to minimize systematic confounding from stroma tissue in any prostate cancer cohort comparing prostate cancer and normal samples. In particular we use samples assessed by histopathology to identify genes enriched and depleted in prostate stroma. These genes are then used to assess stroma content in tissue samples from other prostate cancer cohorts where no histopathology is available. Differential expression analysis is performed by comparing cancer and normal samples where the average stroma content has been balanced between the sample groups. In total we analyzed seven patient cohorts with prostate cancer consisting of 1713 prostate cancer and 230 normal tissue samples. RESULTS: When stroma confounding was minimized, differential gene expression analysis over all cohorts showed robust and consistent downregulation of nearly all genes in the cholesterol synthesis pathway. Additional Gene Ontology analysis also identified cholesterol synthesis as the most significantly altered metabolic pathway in prostate cancer at the transcriptional level. CONCLUSION: The surprising observation that cholesterol synthesis genes are downregulated in prostate cancer is important for our understanding of how prostate cancer cells regulate cholesterol levels in vivo. Moreover, we show that tissue heterogeneity explains the lack of consistency in previous expression analysis of cholesterol synthesis genes in prostate cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4373-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-27 /pmc/articles/PMC5922022/ /pubmed/29703166 http://dx.doi.org/10.1186/s12885-018-4373-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Rye, Morten Beck Bertilsson, Helena Andersen, Maria K. Rise, Kjersti Bathen, Tone F. Drabløs, Finn Tessem, May-Britt Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
title | Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
title_full | Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
title_fullStr | Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
title_full_unstemmed | Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
title_short | Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
title_sort | cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922022/ https://www.ncbi.nlm.nih.gov/pubmed/29703166 http://dx.doi.org/10.1186/s12885-018-4373-y |
work_keys_str_mv | AT ryemortenbeck cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized AT bertilssonhelena cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized AT andersenmariak cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized AT risekjersti cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized AT bathentonef cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized AT drabløsfinn cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized AT tessemmaybritt cholesterolsynthesispathwaygenesinprostatecanceraretranscriptionallydownregulatedwhentissueconfoundingisminimized |